Deutsche Bank raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $300 from $287 following the U.S. Food and Drug Administration’s full approval of Ziihera regimens.
The FDA granted full approval to Ziihera (zanidatamab) as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, covering patients regardless of PD-L1 status. Deutsche Bank analyst David Hoang cited the approval as a catalyst for the upgraded target, noting the absence of anticipated commercialization friction given the label and existing J-code.
Jazz Pharmaceuticals’ shares were up 2.24% at $260.23 in early trading, extending a 108% gain over the past year. The company’s most recent quarterly revenue reached $1.21 billion, exceeding the consensus estimate of $1.11 billion. Earnings per share came in at $5.71, falling short of expectations due to convertible debt dilution and in-process research and development expenses.
Deutsche Bank also expects the National Comprehensive Cancer Network to issue Category 1 recommendations for both Ziihera regimens following its annual meeting in August. The bank’s new target aligns with TD Cowen’s $300 target, while Stifel and Truist Securities have set targets of $275 and $264, respectively. InvestingPro’s fair value estimate for Jazz Pharmaceuticals stands at $294.58.
Ziihera’s peak sales estimate has been increased to a range of $3 billion to $5 billion, up from a prior forecast of more than $2 billion. The positive outlook follows topline data from the Phase 3 HERIZON-GEA-01 trial, released in November 2025.
